Author

Erik J. Asmus

Observed names: Erik J. Asmus, Erik Asmus, Erik J Asmus

Observed institution: Mayo Clinic

OpenAlex ID: A5015118591

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

2017 · Wei Ding, Betsy R. LaPlant, et al. · Blood · 407

Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers

2020 · Gerardo Colon-Otero, Valentina Zanfagnin, et al. · ESMO Open · 99

A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer

2019 · Ashish V. Chintakuntlawar, Jun Yin, et al. · Thyroid · 79

Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial

2022 · Shaji K Kumar, Melissa Alsina, et al. · Blood · 45

Clinical Significance of Circulating Tumor Cells in Hormone Receptor–positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab

2020 · Mark Jesus M. Magbanua, Oleksandr Savenkov, et al. · Clinical Cancer Research · 25

PDF

PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485)

2016 · Wei Ding, Jennifer Le-Rademacher, et al. · Blood · 14

Lenvatinib as a Therapeutic Option in Unresectable Metastatic Pheochromocytoma and Paragangliomas

2022 · Lauren Hassan Nelson, Harry Fuentes-Bayne, et al. · Journal of the Endocrine Society · 13

PDF

Results of a phase 2 trial of ribociclib and letrozole in patients with either relapsed estrogen receptor (ER)-positive ovarian cancers or relapsed ER-positive endometrial cancers.

2019 · Gerardo Colon-Otero, S. John Weroha, et al. · Journal of Clinical Oncology · 9

Randomized phase III trial of eribulin (E) versus standard weekly paclitaxel (P) as first- or second-line therapy for locally recurrent or metastatic breast cancer (MBC).

2020 · Minetta C. Liu, David W. Hillman, et al. · Journal of Clinical Oncology · 7

Initial results of MC200710 investigating therapeutic vaccine (PDS0101) alone or with pembrolizumab prior to surgery or radiation therapy for locally advanced HPV associated oropharyngeal carcinoma, a phase 2 window of opportunity trial.

2025 · David M. Routman, Katharine Andress Rowe Price, et al. · Journal of Clinical Oncology · 5

PDF

Efficacy and safety of iberdomide, daratumumab, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma.

2026 · Prashant Kapoor, Shaji Kumar, et al. · Journal of Clinical Oncology · 3

PDF

A Phase 2 Trial of Protein Kinase C Iota Inhibition With the Combination of Auranofin and Sirolimus in Patients With Recurrent Ovarian Cancer

2025 · Aminah Jatoi, Nathan R. Foster, et al. · American Journal of Clinical Oncology · 3

Phase 1/2 Trial of Carfilzomib and Melphalan Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma (CARAMEL)

2019 · Suzanne Hayman, Betsy LaPlant, et al. · Transplantation and Cellular Therapy · 2

A phase II study of pemetrexed and pembrolizumab in patients (pts) with recurrent and/or metastatic (R/M) salivary gland cancer (SGC): Results from non-adenoid cystic cohort.

2025 · Katharine Andress Rowe Price, Nathan R. Foster, et al. · Journal of Clinical Oncology · 1

Combination of daratumumab, ixazomib, and lenalidomide with or without dexamethasone for initial therapy of newly diagnosed myeloma

2026 · Shaji Kumar, Betsy Knopf, et al. · Blood Cancer Journal

PDF

Phase II Trial of Pemetrexed and Pembrolizumab in Patients With Recurrent and/or Metastatic Nonadenoid Cystic Salivary Gland Cancer

2026 · Katharine Andress Rowe Price, Nathan Foster, et al. · JCO oncology advances.

PDF

Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma

2026 · Shaji Kumar, Betsy Knopf, et al. · Clinical Lymphoma Myeloma & Leukemia

A phase II study of pemetrexed and pembrolizumab in patients (pts) with recurrent and/or metastatic (R/M) salivary gland cancer (SGC): Results from the adenoid cystic cohort.

2026 · Katharine Andress Rowe Price, Nathan Foster, et al. · Journal of Clinical Oncology

A Phase I Trial of Intravenous Vesicular Stomatitis Virus Expressing Thyroidal Sodium Iodide Symporter (NIS) and Human Interferon beta (hIFNβ) in Metastatic or Recurrent Endometrial Cancer

2026 · Simrit K. Warring, Kah-Whye Peng, et al. · SSRN Electronic Journal

PDF

Supplementary Data from Clinical Significance of Circulating Tumor Cells in Hormone Receptor–positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab

2023 · Mark Jesus M. Magbanua, Oleksandr Savenkov, et al.

Data from Clinical Significance of Circulating Tumor Cells in Hormone Receptor–positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab

2023 · Mark Jesus M. Magbanua, Oleksandr Savenkov, et al.

Data from Clinical Significance of Circulating Tumor Cells in Hormone Receptor–positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab

2023 · Mark Jesus M. Magbanua, Oleksandr Savenkov, et al.

Supplementary Data from Clinical Significance of Circulating Tumor Cells in Hormone Receptor–positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab

2023 · Mark Jesus M. Magbanua, Oleksandr Savenkov, et al.

Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma - MRD Negativity and Survival Outcomes

2022 · Shaji K Kumar, Betsy Laplant, et al. · Blood

Clinical significance of circulating tumor cells (CTCs) in hormone receptor-positive (HR+) metastatic breast cancer (MBC) patients (pts) receiving letrozole (Let) or Let plus bevacizumab (Bev): CALGB 40503 (Alliance).

2019 · Mark Jesus Mendoza Magbanua, Oleksandr Oleksandr Savenkov, et al. · Journal of Clinical Oncology

Works count: 25

Citation count: 712

H-index: 8

I10-index: 7